Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JSMO Aims at Health Insurance Coverage of KRAS Gene Testing
April 6, 2009
- Many Patients Hesitate to Request Generic Substitution
April 6, 2009
- Synergism with Millennium to Drive Takeda's Business in Oncology
April 6, 2009
- 12 Drugs and 5 APIs Priced
April 6, 2009
- Falsification of Data Found on World's 1st Recombinant Human Albumin
April 6, 2009
- REGULATORY NEWS IN BRIEF
April 6, 2009
- LDP's Research Commission Calls For More Investment in Pharma R&D
April 6, 2009
- UGT1A1 Gene Polymorphism Testing Reagent from Sekisui Medical
April 6, 2009
- R&D NEWS IN BRIEF
April 6, 2009
- Meiji Seika Licenses Drug for Schizophrenia from ACADIA
April 6, 2009
- 7th JSMO Annual Meeting
April 6, 2009
- Eli Lilly Japan: Sales Up 2% to ¥91,773 Mil.
April 6, 2009
- Aggregates Not Visible with Naked Eye Detected in Kenacort
April 6, 2009
- Mr Matsutani to Step Down as FJPWA President
April 6, 2009
- Pfizer Announces Results of EPPV on Sutent
April 6, 2009
- NEW PRODUCTS
April 6, 2009
- Greater Hypotensive Effects Can Be Expected with Co-DIO: Dr Ogihara
April 6, 2009
- BUSINESS NEWS IN BRIEF
April 6, 2009
- Selective a1-Inhibitors Effective against MS-Associated Dysuria: Prof. Horie
April 6, 2009
- Market Growth for Generics Slowed Down in 4th Qtr of 2008
April 6, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…